188730-05-4

Basic information

• Product Name: (1E)(3S)-3-(tert-butyl-dimethylsilyl)oxy-2-methyl-1-[2-methyl(1,3-thiazol-4-yl)]hexa-1,5-diene
• Synonyms: (1E)(3S)-3-(tert-butyl-dimethylsilyl)oxy-2-methyl-1-[2-methyl(1,3-thiazol-4-yl)]hexa-1,5-diene
• CAS NO: 188730-05-4
• Molecular Weight: 323.575
• Mol File: 188730-05-4.mol

Chemical Properties

• CAS DataBase Reference: (1E)(3S)-3-(tert-butyl-dimethylsilyl)oxy-2-methyl-1-[2-methyl(1,3-thiazol-4-yl)]hexa-1,5-diene(CAS DataBase Reference)
• NIST Chemistry Reference: (1E)(3S)-3-(tert-butyl-dimethylsilyl)oxy-2-methyl-1-[2-methyl(1,3-thiazol-4-yl)]hexa-1,5-diene(188730-05-4)
• EPA Substance Registry System: (1E)(3S)-3-(tert-butyl-dimethylsilyl)oxy-2-methyl-1-[2-methyl(1,3-thiazol-4-yl)]hexa-1,5-diene(188730-05-4)

Safety Data

• Hazardous Substances Data: 188730-05-4(Hazardous Substances Data)

Upstream product

• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 

Downstream Products

• 186692-73-9 desoxyepothilone A 
• 210690-99-6 (2S,6Z,9S,10E)-9-[(1,1-Dimethylethyl)dimethylsilyloxy]-11-(2-methylthiazol-4-yl)-2,6,10-trimethyl-undeca-6,10-dien-1-ol 
• 152044-53-6 epithilone A 
• 355009-08-4 (S)-4-Benzyl-3-[(6E,10E)-(2S,9S)-9-(tert-butyl-dimethyl-silanyloxy)-6-chloromethyl-2,10-dimethyl-11-(2-methyl-thiazol-4-yl)-undeca-6,10-dienoyl]-oxazolidin-2-one 
• 355009-06-2 (S)-4-Benzyl-3-[(E)-(2S,9S)-9-(tert-butyl-dimethyl-silanyloxy)-7-hydroxy-2,10-dimethyl-6-methylene-11-(2-methyl-thiazol-4-yl)-undec-10-enoyl]-oxazolidin-2-one 
• 193146-26-8 (3S,6R,7S,8S,12Z,15S,16E)-3,7-bis{[tert-butyl(dimethyl)silyl]oxy}-15-hydroxy-4,4,6,8,12,16-hexamethyl-17-(2-methyl-1,3-thiazol-4-yl)-5-oxoheptadeca-12,16-dienoic acid 
• 193146-63-3 (12Z,16E)-(3S,6R,7S,8S,15S)-3,7,15-tris-(tert-butyl-dimethyl-silanyloxy)-4,4,6,8,12,16-hexamethyl-17-(2-methyl-thiazol-4-yl)-5-oxo-heptadeca-12,16-dienoic acid 
• 193146-49-5 (7S,10R,11S,12S,19S,Z)-7-(tert-butyldimethylsilyloxy)-11-hydroxy-2,2,3,3,8,8,10,12,16,21,21,22,22-tridecamethyl-19-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,20-dioxa-3,21-disilatricos-16-en-9-one 
• 193146-51-9 (7S,10R,11S,12S,19S,Z)-7,11-bis(tert-butyldimethylsilyloxy)-2,2,3,3,8,8,10,12,16,21,21,22,22-tridecamethyl-19-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,20-dioxa-3,21-disilatricos-16-en-9-one 
• 193146-53-1 (5S,8R,9S,10S,17S,Z)-9-(tert-butyldimethylsilyloxy)-5-(2-hydroxyethyl)-2,2,3,3,6,6,8,10,14,19,19,20,20-tridecamethyl-17-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,18-dioxa-3,19-disilahenicos-14-en-7-one 
• 189453-10-9 epothilone D 
• 189453-35-8 (4S,7R,8S,9S,13Z,16S,1'E)-4,8-di-tert-butyldimethylsilyloxy-5,5,7,9,13-pentamethyl-16-[1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-1-ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione 
• 152044-54-7 epothilone B 

Relevant articles and documents

Total syntheses of epothilones A and B via a macrolactonization-based strategy

The total syntheses of epothilones A (1) and B (2) and several analogues thereof are described. The reported strategy relies on a macrolactonization approach and features selective epoxidation of the macrocycle double bond in precursors 3 and 4 (Scheme 1), respectively, as well as high convergency and flexibility. Building blocks 9-12 and 15 were constructed by asymmetric processes and coupled via Wittig, aldol, and macrolactonization reactions to afford the basic skeleton of epothilones and that of several of their analogues by a relatively short route. The utilization ofintermediate 14, obtained via a stereoselective Wittig reaction and its Enders coupling to SAMP hydrazone 13 (Scheme 8), in combination with a stereoselective aldol reaction with the modified substrate 69 (Scheme 10) improved the stereoselectivity and efficiency of the total synthesis of these new and highly potent microtubule binding antitumor agents.